The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring ...
With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. | With dosing underway in a pivotal phase 3 trial, Star ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback